SCHEMBL916558

SCHEMBL916558

O=C1CC2CCCC(C1)N2S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 7/20 0.62
PSEN2 P49810 7/20 0.62
APH1B Q8WW43 7/20 0.62
NCSTN Q92542 7/20 0.62
APH1A Q96BI3 7/20 0.62
PSENEN Q9NZ42 7/20 0.62
ACHE P22303 2/20 0.62
ALDH1A1 P00352 2/20 0.52
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
MAPK1 P28482 1/20 0.52
CTSG P08311 1/20 0.51
CMA1 P23946 1/20 0.51
MMP2 P08253 1/20 0.47
LMNA P02545 1/20 0.46
PKM P14618 1/20 0.46
HSD11B1 P28845 1/20 0.46
APP P05067 2/20 0.44
KDM2B Q8NHM5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8251036 1.00 PSEN1 (0.62) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL916819 0.93 PSEN1 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2221432 0.88 PSEN1 (0.72) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2220964 0.86 PSEN1 (0.70) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2221045 0.86 PSEN1 (0.60) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL917362 0.86 PSEN1 (0.54) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2219351 0.84 ACHE (0.64) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL917161 0.84 ACHE (0.44) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL917773 0.83 PSEN1 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL12441546 0.83 PSEN1 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178119-A1 Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. (US) 2011-07-21 US claimed
EP-1915371-A2 BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals Inc. (US) 2008-04-30 EP claimed
WO-2007024651-A2 BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-03-01 WO claimed
US-20220396631-A1 TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF NOVARTIS AG (CH) 2022-12-15 US disclosed
US-20110178119-A1 Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. (US) 2011-07-21 US disclosed
US-20110178119-A1 Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. (US) 2011-07-21 US disclosed
US-20110178119-A1 Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. (US) 2011-07-21 US disclosed
US-20110003802-A1 Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003802-A1 Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003802-A1 Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-7754712-B2 Bridged N-cyclic sulfonamido inhibitors of gamma secretase ELAN PHARMACEUTICALS, INC. (US) 2010-07-13 US disclosed
US-7345056-B2 Bridged N-cyclic sulfonamido inhibitors of gamma secretase ELAN PHARMACEUTICALS, INC. (US) 2008-03-18 US disclosed
US-7345056-B2 Bridged N-cyclic sulfonamido inhibitors of gamma secretase ELAN PHARMACEUTICALS, INC. (US) 2008-03-18 US disclosed
WO-2007024651-A2 BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-03-01 WO disclosed
WO-2007024651-A2 BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-03-01 WO disclosed
US-20070049612-A1 Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2007-03-01 US disclosed
US-20070049612-A1 Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2007-03-01 US disclosed
US-20070049612-A1 Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2007-03-01 US disclosed
WO-2007022502-A2 BRIDGED N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-02-22 WO disclosed
WO-2007022502-A2 BRIDGED N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178119-A1 Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 PSEN1 3/4885PSEN2 4/4885APH1B 5/4885
US-20220396631-A1 TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF CD2, CD2BP2, CD22 PSEN1 2781/4885PSEN2 3480/4885APH1B 2992/4885
US-20110003802-A1 Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 PSEN1 3/4885PSEN2 4/4885APH1B 6/4885
US-20070049612-A1 Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 PSEN1 3/4885PSEN2 4/4885APH1B 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.